Group 1 - The core viewpoint of the news is that Yuan Dong Bio has experienced a significant stock price increase of 97.60% this year, despite a recent decline of 2.09% in its stock price [1] - As of December 29, the stock price is reported at 58.70 yuan per share, with a total market capitalization of 10.362 billion yuan [1] - The company has a diverse revenue structure, with 78.75% of its main business income coming from formulation sales, 9.22% from raw material sales, and smaller contributions from technology services and CMO/CDMO [1] Group 2 - As of September 30, the number of shareholders for Yuan Dong Bio has increased by 18.67% to 6,482, while the average circulating shares per person decreased by 15.74% to 27,234 shares [2] - For the period from January to September 2025, the company reported a revenue of 1.019 billion yuan, a year-on-year decrease of 2.00%, while the net profit attributable to the parent company was 220 million yuan, reflecting a year-on-year growth of 1.45% [2] - The company has distributed a total of 341 million yuan in dividends since its A-share listing, with 212 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Yuan Dong Bio has seen a significant increase in its stock price, rising by 5.47% to 55.30 CNY per share, with a trading volume of 150 million CNY and a turnover rate of 1.58%, leading to a total market capitalization of 9.762 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, and listed on September 2, 2020, is primarily engaged in the research, production, and sales of chemical raw materials and chemical drug formulations. The revenue composition is as follows: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - According to data from the top ten holdings of funds, a fund under Bank of China Securities has a significant position in Yuan Dong Bio. The Bank of China Securities Health Industry Mixed Fund (002938) held 146,000 shares in the third quarter, accounting for 5.07% of the fund's net value, ranking as the ninth largest holding. The estimated floating profit today is approximately 419,000 CNY [2] - The Bank of China Securities Health Industry Mixed Fund (002938) was established on September 7, 2016, with a current scale of 159 million CNY. Year-to-date returns are 41.95%, ranking 1861 out of 8155 in its category; the one-year return is 27.34%, ranking 3169 out of 8029; and since inception, the return is 138.44% [2]

Company Overview - Yuandong Biopharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On October 15, Yuandong's stock rose by 5.12%, reaching a price of 54.03 CNY per share, with a trading volume of 42.6 million CNY and a turnover rate of 0.46%. The total market capitalization is 9.538 billion CNY [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Yuandong Biopharmaceutical, with the Guotou Ruijin Healthcare Mixed A Fund (000523) holding 98,300 shares, accounting for 2.96% of the fund's net value, making it the seventh-largest holding. The estimated floating profit today is approximately 258,600 CNY [2] - The Guotou Ruijin Healthcare Mixed A Fund was established on February 25, 2014, with a latest scale of 121 million CNY. Year-to-date returns are 31.89%, ranking 2270 out of 8161 in its category; the one-year return is 25.9%, ranking 2959 out of 8015; and since inception, the return is 150.74% [2]

Group 1 - The core point of the news is that Yuan Dong Bio experienced a 5% drop in stock price, reaching 55.46 CNY per share, with a total market capitalization of 9.79 billion CNY [1] - The company, Chengdu Yuan Dong Bio Pharmaceutical Co., Ltd., was established on June 1, 2009, and went public on September 2, 2020. Its main business involves the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Taiping Fund has a significant position in Yuan Dong Bio. The Taiping Medical Innovation Mixed Fund A (021027) held 11,500 shares in the second quarter, accounting for 3.27% of the fund's net value, ranking as the tenth largest holding [2] - The Taiping Medical Innovation Mixed Fund A (021027) was established on June 4, 2024, with a latest scale of 13.98 million CNY. Year-to-date returns are 56.58%, ranking 854 out of 8171 in its category; the one-year return is 52.42%, ranking 2757 out of 8004; and since inception, the return is 50.71% [2] Group 3 - The fund manager of Taiping Medical Innovation Mixed Fund A (021027) is Lu Lingling, who has been in the position for 1 year and 115 days. The total asset size of the fund is 14.45 million CNY, with the best return during her tenure being 49.45% and the worst return being 48.55% [3]

Group 1 - The core point of the news is that Yuan Dong Bio experienced a 5.01% drop in stock price, reaching 57.80 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 1.29%, resulting in a total market capitalization of 10.204 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, and listed on September 2, 2020, is located in Chengdu, Sichuan Province. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition of Yuan Dong Bio includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - From the perspective of major fund holdings, Hongde Fund has one fund heavily invested in Yuan Dong Bio. The Hongde Medical Innovation Mixed Fund A (012481) held 27,000 shares in the second quarter, accounting for 7.84% of the fund's net value, making it the third-largest holding [2] - The Hongde Medical Innovation Mixed Fund A (012481) was established on February 22, 2023, with a latest scale of 10.4748 million CNY. Year-to-date, it has achieved a return of 56.9%, ranking 799 out of 8173 in its category; over the past year, it has returned 69.53%, ranking 1601 out of 8003; and since inception, it has returned 4.62% [2] - The fund manager of Hongde Medical Innovation Mixed Fund A (012481) is Cao Zhaoxu, who has been in the position for 4 years and 266 days. The total asset scale of the fund is 14.1489 million CNY, with the best return during his tenure being 3.26% and the worst being -35.88% [3]

Core Viewpoint - Yuan Dong Bio's stock price increased by 5% to 62.15 CNY per share, with a total market capitalization of 10.971 billion CNY as of the report date [1] Company Overview - Chengdu Yuan Dong Bio-Pharmaceutical Co., Ltd. was established on June 1, 2009, and went public on September 2, 2020. The company specializes in the research, development, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of the company includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Fund Holdings - The Guotou Ruijin Fund has a significant holding in Yuan Dong Bio, with the Guotou Ruijin Healthcare Mixed A Fund (000523) holding 98,300 shares, accounting for 2.96% of the fund's net value, making it the seventh-largest holding [2] - The fund has achieved a year-to-date return of 41.79%, ranking 1532 out of 8172 in its category, and a one-year return of 58.96%, ranking 2416 out of 7980 [2] Fund Manager Information - The fund manager of Guotou Ruijin Healthcare Mixed A Fund is Liu Zexu, who has been in the position for 2 years and 9 days. The total asset size of the fund is 198 million CNY, with the best return during his tenure being 39.66% and the worst being 24.38% [3]

截至发稿，陆玲玲累计任职时间1年107天，现任基金资产总规模1444.58万元，任职期间最佳基金回报 51.17%， 任职期间最差基金回报50.28%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，太平基金旗下1只基金重仓苑东生物。太平医疗创新混合发起式A（021027）二季度持有股 数1.15万股，占基金净值比例为3.27%，位居第十大重仓股。根据测算，今日浮盈赚取约3.38万元。 太平医疗创新混合发起式A（021027）成立日期2024年6月4日，最新规模1398.27万。今年以来收益 56.86%，同类排名625/8172；近一年收益52.54%，同类排名3130/7980；成立以来收益50.98%。 太平医疗创新混合发起式A（021027）基金经理为陆玲玲。 9月18日，苑东生物涨5.06%，截至发稿，报61.08元/股，成交1.05亿元，换手率1.00%，总市值107.83亿 元。 资料显示，成都苑东生物制药股份有限公司位于四川 ...

Group 1 - The core viewpoint of the news is that Yuan Dong Bio has seen a stock price increase of 5.03%, reaching 55.55 CNY per share, with a total market capitalization of 9.806 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, and listed on September 2, 2020, specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The company's main revenue sources are: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Group 2 - From the perspective of fund holdings, Hongde Fund has a significant position in Yuan Dong Bio, with its Hongde Medical Innovation Mixed Fund A (012481) holding 27,000 shares, accounting for 7.84% of the fund's net value [2] - The fund has generated an estimated floating profit of approximately 71,800 CNY today [2] - The Hongde Medical Innovation Mixed Fund A was established on February 22, 2023, with a current scale of 10.4748 million CNY and has achieved a year-to-date return of 55.59% [2]

Company Overview - Yuan Dong Bio-pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, established on June 1, 2009, and listed on September 2, 2020. The company specializes in the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The main revenue composition includes: 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] Stock Performance - On September 4, Yuan Dong Bio's stock fell by 5.42%, trading at 59.80 yuan per share, with a transaction volume of 86.87 million yuan and a turnover rate of 0.79%. The total market capitalization is 10.557 billion yuan [1] Fund Holdings - Tai Ping Fund has one fund heavily invested in Yuan Dong Bio. The Tai Ping Medical Innovation Mixed Fund A (021027) held 11,500 shares in the second quarter, accounting for 3.27% of the fund's net value, ranking as the tenth largest holding. The estimated floating loss today is approximately 39,400 yuan [2] - The Tai Ping Medical Innovation Mixed Fund A (021027) was established on June 4, 2024, with a latest scale of 13.9827 million yuan. Year-to-date returns are 63.38%, ranking 349 out of 8,180 in its category; one-year returns are 58.77%, ranking 1,728 out of 7,978; and since inception returns are 57.25% [2]

Group 1 - The core viewpoint of the news is that Yuan Dong Bio has seen a significant increase in its stock price, with a rise of 5.08% to 66.20 CNY per share, and a total market capitalization of 11.686 billion CNY [1] - Yuan Dong Bio, established on June 1, 2009, specializes in the research, production, and sales of chemical raw materials and chemical drug formulations, with its main revenue sources being 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO, and 1.22% from other sources [1] - The company has a trading volume of 1.13 million CNY and a turnover rate of 1.00% as of the report date [1] Group 2 - The Hongde Medical Innovation Mixed Fund A (012481) holds a significant position in Yuan Dong Bio, with 27,000 shares, accounting for 7.84% of the fund's net value, making it the third-largest holding [2] - The fund has achieved a year-to-date return of 64.56% and a one-year return of 83.28%, ranking 294 out of 8180 and 684 out of 7967 respectively in its category [2] - The fund was established on February 22, 2023, with a current scale of 10.4748 million CNY [2]